Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Zoetis Inc (ZTS) Price & Performance

CVS Health CorpTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Zoetis Inc — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: CVS Health Corp is far larger — about 3.7× Zoetis Inc's market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Zoetis Inc for 70 Days on average.

CVSZTS
Market Cap
$112.29B$30.20B
Volume
7,763,6766,175,327
Sector
HealthHealth
52-Week High
$110.60$147.53
52-Week Low
$70.08$69.09
Typical Hold Time
83 Days70 Days
Enterprise Value
$174.64B$37.76B
Dividend Yield
3.03%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.80, down 0.17% on the day, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07B in 2025, though net income margin compressed to 1.18%. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.

CVS presents a mixed outlook with solid revenue growth and analyst bullishness (85% buy ratings, $111.20 consensus target) offset by profitability pressures and a bearish technical trend. Key risks include reimbursement pressure and ongoing legal investigations, but the stock offers value with a low P/S of 0.27 and dividend yield support.

Zoetis Inc

Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.

The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS
100% Buy0% Sell
Avg holding period · 83 Days
ZTS

No sentiment data available yet.

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →